Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Orthocell Ltd ( (AU:OCC) ) just unveiled an update.
Orthocell Limited has submitted a regulatory application to the Thai Food and Drug Administration to sell its nerve repair product, Remplir™, in Thailand’s US$84 million market. The company is actively expanding its global reach, targeting significant markets such as the US, Canada, and various Asia-Pacific countries, with approvals expected in 2025. This strategic move aims to capture a substantial portion of the US$3.2 billion global market for nerve repair, enhancing Orthocell’s revenue potential and market presence.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes the CelGro™ platform for tissue reconstruction and Remplir™ for peripheral nerve repair, among other products. Orthocell operates globally, with products cleared for use in various international markets.
YTD Price Performance: 17.65%
Average Trading Volume: 1,732,267
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$389.6M
For an in-depth examination of OCC stock, go to TipRanks’ Stock Analysis page.
